KR-31831, a new synthetic anti-ischemic agent, inhibits in vivo and in vitro angiogenesis
Experimental & Molecular Medicine
; : 502-508, 2006.
Article
in En
| WPRIM
| ID: wpr-181049
Responsible library:
WPRO
ABSTRACT
Angiogenesis is considered to be an integral process to the growth and spread of solid tumors. Anti-angiogenesis therapy recently has been found to be one of the most promising anti-cancer therapeutic strategies. In this study, we provide several lines of evidences showing that KR-31831, a new benzopyran derivative, has anti-angiogenic activities. KR-31831 inhibited the proliferation, migration, invasion and tube formation of bovine aortic endothelial cells (BAECs), and suppressed the release of matrix metalloproteinase-2 (MMP-2) of BAECs. KR-31831 also inhibited in vivo angiogenesis in mouse Matrigel plug assay. Furthermore, the mRNA expressions of basic fibroblast growth factor (bFGF), fibroblast growth factor receptor-2 (FGFR-2), and vascular endothelial growth factor receptor-2 (VEGFR-2) were decreased by KR-31831. Taken together, these results suggest that KR-31831 acts as a novel angiogenesis inhibitor and might be useful for treating hypervascularized cancers.
Key words
Full text:
1
Index:
WPRIM
Main subject:
Benzopyrans
/
Cell Movement
/
Cells, Cultured
/
Fibroblast Growth Factor 2
/
Neovascularization, Physiologic
/
Matrix Metalloproteinase 2
/
Angiogenesis Inhibitors
/
Vascular Endothelial Growth Factor Receptor-2
/
Endothelial Cells
/
Receptor, Fibroblast Growth Factor, Type 2
Type of study:
Prognostic_studies
Limits:
Animals
Language:
En
Journal:
Experimental & Molecular Medicine
Year:
2006
Type:
Article